TGFB1 and systemic sclerosis: Despite this, a decrease in basal fibronectin expression was observed with siCCN2 treatment compared to siNTC treatment, even in SSc fibroblasts not treated with TGF-β (4.62 ± 3.77 vs 27.9 ± 10.8 ADU, p = 0.002).